Greenwich LifeSciences, Inc.
GLSINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GLSI. That does not mean none is planned.
Get an email about GLSI's next catalysts
Track Greenwich LifeSciences (GLSI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
GLSI Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.30 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
GC3107
BCG Vaccination Reaction
GreenGene
Hemophilia A
Hantavax injection
Infection
Tetanus and Diphtheria(Td vaccine)
Bacterial Infections
GC3102C
Prophylaxis Against Influenza
Human immunoglobulin intravenous
Immune Thrombocytopenia
GCPGC
Chemotherapy Induced Neutropenia
Shinbaro Capsule
Osteoarthritis
GC3110A vaccine
Influenza, Human
Adjuvanted influenza A(H1N1) vaccine
Influenza Infection
Immune Globulin Intravenous (Human) Liquid, IVIG-SN™
Immunologic Deficiency Syndrome
LAENNEC (Human Placenta Hydrolysate) IV
Chronic Liver Disease
GC3110A(Quadrivalent)
Influenza
GLSI-100
Breast Cancer
GC1107
Bacterial Infections
GC3110A
Influenza
GC5107
Immunologic Deficiency Syndromes
Hunterase
Hunter Syndrome
Varicella Vaccine
Healthy Children
MG1109
Influenza
cetuximab
Carcinoma, Non-Small-Cell Lung
GC1102
Hepatitis B Infection
CBD
Diabetic Neuropathies
GC3114
Influenza, Human
GHB16L2
Influenza, Human
GHB11L1
Influenza, Human
Quadrivalent cell-culture based influenza vaccin
Influenza
Quadrivalent influenza vaccine
Influenza
Step 1
Influenza
MG1111 (BARICELA)
Varicella
GC1111_
Mucopolysaccharidosis II
GC5131
Covid19
Immunoglobulin G
Autoimmune Encephalitis
LAENNEC (Human Placenta Hydrolysate)
Chronic Liver Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GC3107 | Phase 3 | BCG Vaccination Reaction | - | - |
GreenGene | Phase 3 | Hemophilia A | - | - |
Hantavax injection | Phase 3 | Infection | - | - |
Tetanus and Diphtheria(Td vaccine) | Phase 3 | Bacterial Infections | - | - |
GC3102C | Phase 3 | Prophylaxis Against Influenza | - | - |
Human immunoglobulin intravenous | Phase 3 | Immune Thrombocytopenia | - | - |
GCPGC | Phase 3 | Chemotherapy Induced Neutropenia | - | - |
Shinbaro Capsule | Phase 3 | Osteoarthritis | - | - |
GC3110A vaccine | Phase 3 | Influenza, Human | - | - |
Adjuvanted influenza A(H1N1) vaccine | Phase 3 | Influenza Infection | - | - |
Immune Globulin Intravenous (Human) Liquid, IVIG-SN™ | Phase 3 | Immunologic Deficiency Syndrome | - | - |
LAENNEC (Human Placenta Hydrolysate) IV | Phase 3 | Chronic Liver Disease | - | - |
GC3110A(Quadrivalent) | Phase 3 | Influenza | - | - |
GLSI-100 | Phase 3 | Breast Cancer | - | - |
GC1107 | Phase 3 | Bacterial Infections | - | - |
GC3110A | Phase 3 | Influenza | - | - |
GC5107 | Phase 3 | Immunologic Deficiency Syndromes | - | - |
Hunterase | Phase 3 | Hunter Syndrome | - | - |
Varicella Vaccine | Phase 3 | Healthy Children | - | - |
MG1109 | Phase 3 | Influenza | - | - |
cetuximab | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
GC1102 | Phase 2 | Hepatitis B Infection | - | - |
CBD | Phase 2 | Diabetic Neuropathies | - | - |
GC3114 | Phase 2 | Influenza, Human | - | - |
GHB16L2 | Phase 2 | Influenza, Human | - | - |
GHB11L1 | Phase 2 | Influenza, Human | - | - |
Quadrivalent cell-culture based influenza vaccin | Phase 2 | Influenza | - | - |
Quadrivalent influenza vaccine | Phase 2 | Influenza | - | - |
Step 1 | Phase 2 | Influenza | - | - |
MG1111 (BARICELA) | Phase 2 | Varicella | - | - |
GC1111_ | Phase 2 | Mucopolysaccharidosis II | - | - |
GC5131 | Phase 2 | Covid19 | - | - |
Immunoglobulin G | Phase 2 | Autoimmune Encephalitis | - | - |
LAENNEC (Human Placenta Hydrolysate) | Phase 2 | Chronic Liver Disease | - | - |
Frequently asked questions
What is in Greenwich LifeSciences, Inc.'s drug pipeline?→
CatalystAlert tracks 34 drug candidates in Greenwich LifeSciences, Inc.'s (GLSI) pipeline across Phase 3, Phase 2. Its lead program is Adjuvanted influenza A(H1N1) vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Greenwich LifeSciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Greenwich LifeSciences, Inc. (GLSI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLSI biotech catalysts?→
Add GLSI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Greenwich LifeSciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.